We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Slaps China’s Zhejiang Hisun With Warning Letter for Alleged Data Manipulation
FDA Slaps China’s Zhejiang Hisun With Warning Letter for Alleged Data Manipulation
A December FDA warning letter to China’s Zhejiang Hisun Pharmaceutical released Tuesday outlines the company’s “systemic data manipulation” and cGMP deficiencies uncovered during a March 2015 inspection.